Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...
The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback